News & Announcements

A recent article on the potential for collaborations between universities and companies highlighted the University of Minnesota's role in bolstering the region's medical devices industry. 

On January 19, 2018, changes to regulations for protecting human research participants (also known as the revised “Common Rule”) were scheduled to take effect. We learned on January 17 that the revised Common Rule will be delayed for six months. The new compliance date is now July 19, 2018.

A mobile survey tool developed at the U of M will provide city planners with the data needed to make better transportation decisions. 

The University of Minnesota is one of many contributors to Minnesota's strong economic performance in recent years. 

A significant revision to the Common Rule, also known as the Federal Policy for the Protection of Human Subjects, will go into effect on January 19, 2018.

University researchers helped the Vercise Deep Brain Stimulation System for Parkinson's treatment reach FDA approval.

Following a clinical study led in part by a U of M neurologist, Boston Scientific has received FDA approval for its Vercise Deep Brain Stimulation system.

Workshops at the U of M aim to encourage nurses to develop new medtech ideas into marketable technologies.

Boston Scientific's Vercise system for treating Parkinson's disease, tested in clinical trials led in part by a U of M neurologist, has received FDA approval.

The NIH sIRB policy is effective for NIH grant applications with due dates on or after January 25, 2018. For contracts, the policy applies to all solicitations issued on or after January 25, 2018. At this time, the University of Minnesota is not agreeing to serve as the sIRB, though this may change in the future.